Primary Immunodeficiency Diseases (PID) Clinical Trials

43 clinical trials for Primary Immunodeficiency Diseases (PID) across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency — RECRUITING
• Long-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD) — RECRUITING · PHASE3
• Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID) — RECRUITING · PHASE3
• Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders — RECRUITING · NA
• PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES (RAINBOW TRIAL) — RECRUITING · PHASE1
• CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM 01 TRIAL — RECRUITING · PHASE3
• AN OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF IGSC 20% ADMINISTERED FOR 6 MONTHS IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY — RECRUITING
• CLINICAL PHASE III STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, TOLERABILITY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM 16.5%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES — RECRUITING · PHASE3
• REDUCING-INTENSITY CONDITIONING FOR CHILDREN AND ADULTS WITH HEMOPHAGOCYTIC SYNDROMES OR SELECTED PRIMARY IMMUNE DEFICIENCIES (RICHI) — RECRUITING
• CLINICAL STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF IMMUNOGLOBULIN INTRAVENOUS (HUMAN) 10% (NEWGAM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES — COMPLETED · PHASE3
• Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in the USA and Czech Republic — OTHER
• Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency — COMPLETED · NA
• A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants — COMPLETED · PHASE3
• A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases — ACTIVE_NOT_RECRUITING · PHASE3
• Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency — NOT_YET_RECRUITING
• A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — COMPLETED · PHASE2
• Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD) — OTHER · PHASE3
• Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion — ACTIVE_NOT_RECRUITING · NA
• Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan — COMPLETED
• Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia — COMPLETED
• At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill — COMPLETED
• Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients — NOT_YET_RECRUITING · PHASE3
• A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) — COMPLETED · PHASE3
• Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study — NOT_YET_RECRUITING
• A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) — COMPLETED · PHASE3
• Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects — COMPLETED · PHASE3
• Exercise Capacity, Physical Activity Level and Quality of Life in Children With Primary Immunodeficiency — OTHER
• Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies — OTHER
• Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects — COMPLETED · PHASE4
• Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global) — COMPLETED
• Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) — COMPLETED · PHASE2
• Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders — COMPLETED · PHASE3
• Phase 2/3 Study of IGSC, 20% in PIDD — COMPLETED · PHASE2
• Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID — COMPLETED · PHASE3
• Gammagard Liquid and rHuPH20 in PID — COMPLETED · PHASE3
• Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD — COMPLETED · PHASE2
• Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects — COMPLETED · PHASE2
• Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously — COMPLETED · PHASE1
• Immune Globulin Subcutaenous (Human), 20% — COMPLETED · PHASE2
• Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN) — COMPLETED
• "A PHASE III, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY AND PHARMACOKINETICS OF KEDRION INTRAVENOUS IMMUNOGLOBULIN (IVIG) 10% IN PRIMARY IMMUNODEFICIENCY DISEASE (PID) PATIENTS." — COMPLETED · PHASE3
• A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases — COMPLETED · PHASE3
• A CLINICAL STUDY OF IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN) 20% SOLUTION (IGSC,20%) FOR THE EVALUATION OF EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES — NOT_YET_RECRUITING

Refine this search